Drug intelligence / Profile preview

ropinirole + dextromethorphan

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a **combination of ropinirole and dextromethorphan**. - **Ropinirole** is a non-ergoline dopamine agonist primarily used to treat Parkinson’s disease and restless legs syndrome. It selectively binds to D2 dopamine receptors in the central nervous system, modulating dopaminergic activity, which improves motor and sleep symptoms in these disorders[2][8]. - **Dextromethorphan** is an NMDA receptor antagonist and sigma-1 receptor agonist, mainly used as a cough suppressant. It is also under investigation for several neurologic and psychiatric indications due to its effects on glutamatergic and sigma-1 receptor systems[1][7]. - The combination of these two agents may be investigated for neuropsychiatric or movement disorder indications, but no branded formulation or clinical precedence for this specific dual combination is reported in major databases as of the present date.

02

Targets

ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)σR (Sigma receptors)NMDAR (Glutamate receptor ionotropic, NMDA)CHRNA3 (nAChR α3 subunit)CHRNB4 (nAChR β4 subunit)SIGMAR1 (Sigma non-opioid intracellular receptor 1)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on ropinirole + dextromethorphan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ropinirole + dextromethorphan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call